Free shipping on all orders over $ 500

Verteporfin (CL 318952)

Cat. No. M3539

All AbMole products are for research use only, cannot be used for human consumption.

Verteporfin (CL 318952) Structure
Synonym:

CL 318952; BPD-MA

Size Price Availability Quantity
2mg USD 50  USD50 In stock
5mg USD 85  USD85 In stock
10mg USD 130  USD130 In stock
25mg USD 260  USD260 In stock
50mg USD 380  USD380 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin (CL 318952) is a YAP inhibitor that disrupts YAP-TEAD interactions, and it is also an inhibitor of autophagy that blocks autophagy at an early stage by inhibiting autophagosome formation.

Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells.

Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T.

Chemical Information
Molecular Weight 718.79
Formula C41H42N4O8
CAS Number 129497-78-5
Solubility (25°C) DMSO 50 mg/mL
DMF 10 mg/mL (ultrasonic and warming)
Storage 2-8°C, protect from light
References

[1] Bailey V Fearing, et al. JOR Spine. Verteporfin treatment controls morphology, phenotype, and global gene expression for cells of the human nucleus pulposus

[2] Jian Chen, et al. J Cell Physiol. IL-6/YAP1/β-catenin signaling is involved in intervertebral disc degeneration

[3] Takanobu Morishita, et al. Oncotarget. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib

[4] Yi Liu-Chittenden, et al. Genes Dev. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

[5] U Schmidt-Erfurth, et al. Surv Ophthalmol. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration

Related YAP Products
BAY-593 

BAY-593 is an orally active GGTase-I inhibitor.

SWTX-143 

SWTX-143 is a novel covalent YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms.

YAP-TEAD-IN-1

YAP-TEAD-IN-1 is a potent and competitive inhibitor of YAP–TEAD interaction (IC50=25 nM).

IAG933

IAG933 is a first-in-class, selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor. IAG933 specifically abrogates the interaction between YAP/TAZ coactivators and all four TEAD isoforms, thus selectively inhibiting TEAD-driven transcriptional activity and inducing anti-cancer effects.

Lappaol F

Lappaol F, a lignin, is an anticancer agent.

  Catalog
Abmole Inhibitor Catalog




Keywords: Verteporfin (CL 318952), CL 318952; BPD-MA supplier, YAP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.